Literature DB >> 30731178

Incidence and risk of developing photosensitivity with targeted anticancer therapies.

Kathryn T Ciccolini1, Joseph Kim2, Soham P Chaudhari3, Anna Skripnik Lucas1, Benjamin Benhuri4, Juanita Duran5, Shenhong Wu6, Mario E Lacouture7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30731178      PMCID: PMC6800168          DOI: 10.1016/j.jaad.2019.01.077

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  5 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

3.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

4.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

5.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Authors:  Sophie Leboulleux; Lars Bastholt; Thomas Krause; Christelle de la Fouchardiere; Jan Tennvall; Ahmad Awada; José Manuel Gómez; Françoise Bonichon; Laurence Leenhardt; Christine Soufflet; Muriel Licour; Martin J Schlumberger
Journal:  Lancet Oncol       Date:  2012-08-14       Impact factor: 41.316

  5 in total
  3 in total

1.  Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.

Authors:  William Queiroz Guimarães Wiegandt Ceglio; Marina Mattos Rebeis; Marcela Ferreira Santana; Denis Miyashiro; Jade Cury-Martins; José Antônio Sanches
Journal:  An Bras Dermatol       Date:  2021-11-26       Impact factor: 1.896

Review 2.  Anticancer treatments and photosensitivity.

Authors:  V Sibaud
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-06       Impact factor: 9.228

3.  Photosensitive rash induced by nivolumab.

Authors:  Francisco J Navarro-Triviño; Ricardo Ruiz-Villaverde
Journal:  An Bras Dermatol       Date:  2022-07-07       Impact factor: 2.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.